Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (1917)	10/2/2007 5:09:11 PM
From: Jibacoa	Respond to of 3722

PANC Seems to have found support at the 1.54 level. bigcharts.marketwatch.com The stock tanked on Sep 25 after trying to make a base at the 2.50 level & went through its L of Aug 7 in spite of some recent insider buying.<g> The Sep drop was after it announced the resignation of its CFO & data for its bevirimat for HIV will be pushed back into the 4thQ.Bevirimat is in PIIb to treat HIV,a tablet formulation failed in testing & PANC reverted to using a liquid preparation, while it continues to try to find a tablet formulation that works.It's the first of a new group of maturation inhibitors considered to be HIV antivirals.The PIIb results were encouraging & further data was expected on the 3rdQ. (PANC needs to show that the results on the 300mgs treated group are better than in the 250mgs group.) PANC Has been on a near term DT since it found resistance in April at the $5 level. bigcharts.marketwatch.com But its longer term DT dates from previous Hs, as is attempted rally in June 2003 was cut short at the 39.80 level bigcharts.marketwatch.com PANC Isn't doing well AHs, but if the stock can get back to the $2.50 level it would be a 30% gain from present levels.<g> bigcharts.marketwatch.com Bernard